Action Participants - Core Group
Prof. Sabrina Pricl (email@example.com)
Working Groups 1, 2, 3 and 4
Molecular Biology and Nanotechnology Lab (MolBNL@UniTS)
Department of Engineering and Architecture
University of Trieste
Prof. Pricl's group is active in the discovery of new cancer nanomedicines from computer-assisted design to their in vitro activity. The MolBNL@UniTS Lab has access to local and national/international supercomputers for the in silico studies, synchrotron radiation facility for structural studies, different spectroscopic, spectrophotometric, and other analytical instruments for nanomedicine characterization, including CD-based stopped-flow apparatus, and isothermal titration calorimetry for kinetic and thermodynamic measurements. Different naive and drug-resistant cell lines are also available for in vitro efficacy of nanomedicines.
Dr. Nazende Günday Türeli (N.Guenday-Tuereli@mybiotech.de)
Working Groups 2 and 4
Research & Development Department
MJR PharmJet is a provider of analytical and formulation development services for (bio)pharmaceuticals with a special focus on the low soluble substances. R&D activities offer the development of a broad range of particle types and technologies to cover the needs for achieving enhanced bioavailability or stability, ER or MR formulations. Innovative particle formulations are designed to maximize the benefits of the particulate systems based on application route. Formulation expertise covers not only particulate system development but also integration of those to existing down processing methods such as wet granulation, lyophilization or spray drying to shorten the time to market.
Prof. Maria Francesca Ottaviani (firstname.lastname@example.org)
STSM coordinator, MC member
Working Group 2
Laboratory of Physical Chemistry, Department of Pure and Applied Sciences (DiSPeA)
University of Urbino Carlo Bo'
Prof. Ottaviani's group is characterizing new drugs and drug carriers, mainly dendrimers and surfactant aggregates (like micelles, liposomes, and microemulsions) and their interactions with cell lines, mostly cancer lines compared to healthy lines. Physico-chemical characterization of the bio-relevant molecules and their interactions is mainly performed by an in-situ technique, namely the electron paramagnetic resonance (EPR) spectroscopy, by means of selected spin probes and spin labels. A computer-aided analysis of the results provided unique and specific structural and dynamical information.
Dr. Joanna Korczynska (email@example.com)
CA 17140 GH Manager
University of Lodz
Dr. Joanna Korczynska is the Grant Holder Manager of CA17140. She is the CA17140 administrative chief officer and the reference key person for all matters concerning the administrative and bureaucratic aspects of the Action.
Prof. Barbara Klajnert-Maculewicz (firstname.lastname@example.org)
GH scientific representative, MC member
Working Group 3
Department of General Biophysics
University of Lodz
Prof. Barbara Klajnert-Maculewicz's group concentrates on using different nanosystems (especially dendrimers) as drug carriers in cancer therapies. We are studying complexes with photosensitizers used in photodynamic therapy, complexes with nucleotide analogs, and conjugates with anticancer drugs and monoclonal antibodies. We possess cell culture laboratory with access to flow cytometer and confocal microscope, and biophysical laboratory equipped with spectrofluorimeters, CD spectrometer, zeta-sizer).
Prof. Rana Sanyal (email@example.com)
Working Group 1 leader, MC member
Working Groups 1, 3 and 4
Department of Chemistry, Center for Life Sciences and Technologies
http://www.chem.boun.edu.tr/Prof. Sanyal’s group is synthesizing nanomedicines for targeting cancer. The laboratory activity includes synthesis of polymers and nanoparticles, characterization, in vitro and in vivo studies. A list of currently available facilities at Prof. Sanyal’s lab can be found at https://lifesci.boun.edu.tr/en and https://sanyalgroup.boun.edu.tr/
Dr. Tomáš Strašák (firstname.lastname@example.org)
Working Group 1 vice-leader, MC substitute member
Working Group 1
Department of Bioorganic Compounds and Nanocomposites
Institute of Chemical Process Fundamentals of the Czech Academy of Science
Prague, Czech Republic
Dr. Strašák’s lab is working on rational design of dendrimers and complex macromolecular and supramolecular systems based on dendritic compounds. The products of our research are finding applications in gene therapy or in targeted transport of drugs including chemotherapeutics and their conjugates with saccharides, that we are currently developing. Our lab has access to several analytical tools including NMR, IR, UV-Vis, HRMS , DLS, etc.
Dr. Ivana Vinković Vrček (email@example.com)
Working Group 2 leader, MC member
Working Groups 2, 3 and 4
Analytical Toxicology and Mineral Metabolism Unit
Institute for Medical Research and Occupational Health
Dr. Vinković Vrček’s group is focused on nanosafety and risk/benefit ratio assessment of nano-enabled medicines and medical devices. Their research activities cover all aspects of Safe-by-Design approach: from design, synthesis and chemico-physical characterization to in vitro/in vivo evaluation.
Dr. Evgeny K. Apartsin (firstname.lastname@example.org)
Working Group 2 vice-leader
NCC MC observer
Working Groups 1 and 2
Laboratory of RNA Chemistry
Institute of Chemical Biology and Fundamental Medicine
Dr. Apartsin is involved in the development of new materials for the delivery of therapeutic nucleic acids. In particular, he deals with dendrimer-based and liposome-based nucleic acid carriers (in close collaboration with other COST partners). The Laboratory of RNA Chemistry possesses the necessary equipment and experience for the synthesis and purification of oligonucleotides, organic synthesis as well as physicochemical studies.
Prof. Carlo V. Catapano (email@example.com)
Working Group 3 leader, MC member
Working Groups 3 and 4
Department of Tumor Biology and Experimental Therapeutics
Institute of Oncology Research (IOR) and Università della Svizzera italiana (USI)
My group is investigating transcriptional, epigenetic, and metabolic processes in human cancers and developing innovative therapeutic strategies based on small molecules, oligonucleotides, and small interfering RNAs. These processes underlie the tumor heterogeneity and phenotypic reprogramming associated with stemness, metastasis, tumor progression, and treatment resistance. We have established protocols and in vitro/in vivo experimental models to study these aspects and testing delivery and efficacy of novel therapeutics.
Prof. Ulf Kahlert (firstname.lastname@example.org)
Working Group 3 vice-leader
Working Group 3
Molecular and Experimental Surgery (MES)
Prof. Kahlert´s work exploits stem cell technologies for the development of precision medicine. His efforts are focused on the clinical translational aspects of stem cell biology in a global growing clinical need: oncology. His work bridges developmental biology, stem cell sciences, chemistry, and surgical oncology, requiring the development and exploitation of structured networks incorporating basic science, biotechnology, data science, and conservative and surgery. In Magdeburg, his translational, application-oriented research focuses on the following clinical relevant areas: a) personalized in vitro patient avatar platform for colon, pancreas, and hepatocellular cancer patients to develop improved therapy such as selecting optimal neoadjuvant care or diminish residual tumor cells to metastatic spread of the disease. b) Intraoperative molecular diagnostics to allow intraoperative targeted therapy application to improve robotic surgery performance. He utilizes nanotechnology to optimize the therapeutic potential of drug and drug candidates. On the basic research side, he investigates the relevance of peripheral nerve – to- pancreas/colon tumor cell interaction for tumorigenesis and the emergence of therapy resistance. He serves as an accredited member in international standardization committees such as ISO or D.I.N. e.V.
Dr. Maria Eugenia Riveiro (email@example.com)
Working Group 4 leader, Action dissemination manager, and MC member
Working Groups 3 and 4
Early Drug Development Group, SAS (E2DG)
E2DG is specialized in the early development of novel leads and targets in oncology. In the last 20 years, we worked in the evaluation of over 15 different oncology leads (at least 8 first-in-man), covering both small molecules, monoclonal antibodies, or novel technologies as nanomedicines in oncology. Currently, as E2DG’s Chief Scientific Officer, I support our collaborators to optimize and accelerate their R&D programs, from lead optimization to Phase I clinical trials in oncology. In addition, I am specialized in molecular pharmacology assessments, PK/ADME and CMC regulatory compliance, and intellectual property rights in biotechnology companies.
Dr. Enrico Catalano (firstname.lastname@example.org)
Working Group 4 vice-leader
Working Groups 2, 3 and 4
Scuola Normale Superiore
Dr. Catalano's research focuses on dual tumor-targeting therapy on breast cancer cells based on drug-bioconjugated iron-oxide nanoparticles. His research wants to achieve a smart nanomedicine platform of targeted drug delivery for cancer treatments based on magnetic properties of iron-oxide nanoparticles that overcomes multiple biological barriers for cancer drug delivery to target accurately the cancer site with magnetic nanoparticles under the influence of an external magnetic field. The aim of his research is to produce a dual-targeted drug delivery system and magnetic hyperthermia for more effective treatment of breast cancer by using functionalized iron-oxide nanoparticles (SPIONs) loaded with drugs/targeting moieties which will able to be localized in target tissues and internalized within the desired cells by application of an external magnetic field. The framework of the project aims to implement in vitro experiments for an extremely innovative multi-therapeutic strategy that combines targeted drug delivery of chemotherapeutics, the use of SPIONs properties of hyperthermia to target in vitro breast cancer drug-resistant and not drug-resistant cell lines.